Earnings Data
Report Date
Jul 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.77Last Year’s EPS
0.81Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mixed but constructive picture: top-line growth (net sales +6%) and standout category performance (double-digit fragrance & beauty growth; pet food volumes +11%) combined with strong cash flow guidance and a modestly raised full-year EPS range. Offsetting these positives were a 4% decline in adjusted EBIT, a slight drop in adjusted EPS, short-term resin-related cost pressure (Q2 EBIT drag ~ $10M), weather-related volume disruptions, and a 10% decline in Custom Containers sales driven by destocking and exits. Management emphasized confidence in execution, Weener integration, an active M&A pipeline, and the ability to absorb near-term inflation through contractual pass-throughs and pricing over time, supporting a cautiously optimistic outlook.Company Guidance
Revenue Growth
Net sales of $1.6 billion for Q1 2026, up 6% versus the prior year, driven primarily by contractual pass-through of higher raw material costs and favorable foreign currency translation.
Fragrance & Beauty Outperformance
Dispensing and specialty closures delivered another quarter of double-digit organic volume growth in fragrance and beauty, reflecting strong innovation-led wins and an expanding launch pipeline.
Metal Containers Strength — Pet Food
Metal Containers sales increased 15% year-over-year; volumes rose 2% overall with pet food volumes up 11%, driven by sustained mid-single-digit demand in wet pet food segments.
Weener Integration and Innovation Runway
Weener portfolio fully integrated; combined innovation engines described as providing ample runway to deliver organic growth well in excess of the market in strategic dispensing products for years to come.
Confirmed Strong Cash Generation and CapEx Plan
Full-year 2026 free cash flow confirmed at approximately $450 million and planned CapEx of approximately $310 million, indicating strong cash generation and investment capacity.
Raised Full-Year EPS Range
Company increased 2026 adjusted EPS range by $0.03 to $3.73–$3.93 (versus $3.72 in 2025), reflecting stronger-than-expected operational performance in Q1.
Interest Expense and Balance-Sheet Management
Anticipated interest expense for 2026 reduced to approximately $200 million (improvement versus prior expectation); management highlighted improved treasury initiatives and favorable credit amendment pricing.
Health Care Business Growth
Health care dispensing applications continue to expand; management noted the business is closer to $250 million (up from ~$200 million previously discussed) with targeted growth in nasal and ophthalmic applications.
Active M&A Pipeline and Proven Integration Track Record
Management reiterated an active M&A pipeline and consistent capital deployment discipline, citing the $1 billion Weener deal and rapid deleveraging as evidence of ability to execute acquisitions across sizes.
CH:SL3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FAQ
When does Silgan (CH:SL3) report earnings?
Silgan (CH:SL3) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
What is Silgan (CH:SL3) earnings time?
Silgan (CH:SL3) earnings time is at Jul 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Silgan stock?
The P/E ratio of Silgan Holdings is N/A.
What is CH:SL3 EPS forecast?
CH:SL3 EPS forecast for the fiscal quarter 2026 (Q2) is 0.77.